State-Of-The-Art Diagnostic
Pathology Services


NovaDX - Quality Laboratory Services for Today’s Clinician

  • We offer state-of-the-art technology to diagnose small fiber neuropathy and multiple menu options for fungal and bacterial pathogens

  • At NovaDX, it is our goal to facilitate in faster reporting times and better outcomes for patients. Our services can reduce overall healthcare costs, unnecessary surgeries and treatments, and improve patient care.


Education & Research

  • Specializing in you – the physician. You specialize in your patients; we specialize in you. That’s why you can count on us to deliver the best product and specialized education.
  • We offer in-office and staff training for the biopsy procedure, packaging, and shipment.
  • We offer comprehensive education modules for both patients and healthcare professionals.
  • Interested in ENFD testing to assess the progression of neuropathy and the response to your treatments, we are happy to help use ENFD testing as a measure of outcome on clinical trials.

Key Points

Epidermal Nerve Fiber Density (ENFD)

  • Skin biopsy for Epidermal Nerve Fiber Density (ENFD) testing is a reliable tool for diagnosing small-fiber neuropathy (SFN).
  • The sensitivity of skin biopsy in diagnosing small fiber neuropathy has been reported to be 88%.
  • This is in comparison to 54% for the clinical examination, and 49% for quantitative sensory testing (1).
  • The specificity of the test is 98% (1).
  • Many diseases are associated with SFN such as diabetic neuropathy, alcoholic neuropathy, medication-induced neuropathy, fibromyalgia, and others -> see our education module!
  • Skin biopsy is a safe procedure with minimal discomfort that allows somatic fibers carrying temperature and pain sensation to be differentiated from autonomic fibers.
  • Loss of epidermal nerve fibers correlates with increased severity of neuropathy and a higher risk of developing neuropathic pain.
  • Skin nerve fibers are able to regenerate, and their regrowth rate could be a marker of early axonal damage in patients at risk of developing peripheral neuropathy.
  • A skin biopsy can be repeated in close proximity to a previous biopsy in order to assess the progression of neuropathy and the response to neuroprotective treatments and can be used as a measure of outcome in clinical trials.